{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:51:13Z","timestamp":1724082673701},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00280-012-1825-y","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T12:22:36Z","timestamp":1328012556000},"page":"1255-1263","source":"Crossref","is-referenced-by-count":19,"title":["Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers"],"prefix":"10.1007","volume":"69","author":[{"given":"Adam","family":"del Corral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Dutreix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Huntsman-Labed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Morganroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,1]]},"reference":[{"key":"1825_CR1","unstructured":"Manley PW, Boulton C, Caravatti G, Gilliland DG, Griffin J, Kung A, Kelly L, Maira M, Mestan J, Meyer T, Ruetz S, Weisberg E, Fabbro D (2003) Preclinical profile of PKC412 (Midostaurin) as an FLT3 inhibitor for the therapy of AML. AACR: Poster 1004"},{"key":"1825_CR2","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1182\/blood-2007-11-125476","volume":"113","author":"F Breitenbuecher","year":"2009","unstructured":"Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C, Fischer T (2009) Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 113:4074\u20134077","journal-title":"Blood"},{"key":"1825_CR3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00062752-200207000-00003","volume":"9","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD (2002) Role of FLT3 in leukemia. Curr Opin Hematol 9:274\u2013281","journal-title":"Curr Opin Hematol"},{"key":"1825_CR4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","volume":"114","author":"S Kayser","year":"2009","unstructured":"Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, Groner S, Spath D, Krauter J, Ganser A, Dohner H, Fischer T, Dohner K, German-Austrian AML Study Group (AMLSG) (2009) Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 114:2386\u20132392","journal-title":"Blood"},{"key":"1825_CR5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","volume":"115","author":"KW Pratz","year":"2010","unstructured":"Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M (2010) FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 115:1425\u20131432","journal-title":"Blood"},{"key":"1825_CR6","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","volume":"28","author":"T Fischer","year":"2010","unstructured":"Fischer T, Stone RM, DeAngelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ (2010) Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28:4339\u20134345","journal-title":"J Clin Oncol"},{"key":"1825_CR7","first-page":"634","volume":"114","author":"RM Stone","year":"2009","unstructured":"Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, Rai S, Giles F (2009) A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. ASH Ann Meet Abst 114:634","journal-title":"ASH Ann Meet Abst"},{"key":"1825_CR8","doi-asserted-by":"crossref","unstructured":"Stone RM, Dohner H, Ehninger G, Villeneuve M, Teasdale T, Virkus JD, Bressler LR, Seiler MM, Marcucci G, Larson RA, and on behalf of all study investigators (2011) CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin\/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. J Clin Oncol 29:TPS199","DOI":"10.1200\/jco.2011.29.15_suppl.tps199"},{"key":"1825_CR9","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish network on mastocytosis (REMA) in a series of 113 patients. Blood 108:2366\u20132372","journal-title":"Blood"},{"key":"1825_CR10","doi-asserted-by":"crossref","unstructured":"Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C, Dutreix C, Gross S, Nikolova Z, Graubert T (2010) KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood 116: Abstract 316","DOI":"10.1182\/blood.V116.21.316.316"},{"key":"1825_CR11","doi-asserted-by":"crossref","unstructured":"Gotlib J, Kluin-Nelemans H, Mauro M, Hermine O, Hexner E, Lipton JH, Awan F, Nikolova Z, Gross S, Dutreix C, Dharan B, George T, Horny P, Akin C, Hartmann K, Valent P, Reiter A (2011) A global, phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD). J Clin Oncol 29: Abstract TPS200","DOI":"10.1200\/jco.2011.29.15_suppl.tps200"},{"key":"1825_CR12","doi-asserted-by":"crossref","first-page":"e14540","DOI":"10.1200\/jco.2009.27.15_suppl.e14540","volume":"27","author":"C Dutreix","year":"2009","unstructured":"Dutreix C, Huntsman Labed A, Roesel J, Lanza C, Wang Y (2009) Midostaurin: review of pharmacokinetics (PK) and PK\/pharmacodynamic (PD) relationship in AML\/MDS patients. J Clin Oncol 27:e14540","journal-title":"J Clin Oncol"},{"key":"1825_CR13","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011\u20132019","journal-title":"Lancet"},{"key":"1825_CR14","unstructured":"Tasigna (nilotinib) [package insert]. Stein, Switzerland: Novartis Pharma AG. June 2010"},{"key":"1825_CR15","unstructured":"Sprycel (dasatinib) [package insert]. Princeton NJ Bristol-Myers Squibb Company. October 2010"},{"key":"1825_CR16","unstructured":"Trikha M, Cortes J, Foran J, Ghirdaladze D, DeVetten M, Zodelava M, Holman P, Levis M, Kantarjian H, Borthakur G, James J, Armstrong R, Zarrinkar P, Padre N, Wierenga W, Corringham R (2010) AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase inhibitor in a first-in-human phase 1 AML study. Haematologica 96: Abstract 1117"},{"key":"1825_CR17","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","volume":"108","author":"DJ DeAngelo","year":"2006","unstructured":"DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC (2006) Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108:3674\u20133681","journal-title":"Blood"},{"key":"1825_CR18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-010-1372-3","volume":"67","author":"AW Tolcher","year":"2011","unstructured":"Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67:751\u2013764","journal-title":"Cancer Chemother Pharmacol"},{"key":"1825_CR19","unstructured":"US Food and Drug Administration (2008) ICH guidance for industry: E14 sp: clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs"},{"key":"1825_CR20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0091270008318006","volume":"48","author":"Y Wang","year":"2008","unstructured":"Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H (2008) Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. J Clin Pharmacol 48:763\u2013775","journal-title":"J Clin Pharmacol"},{"key":"1825_CR21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","volume":"73","author":"GJ Noel","year":"2003","unstructured":"Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R (2003) Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 73:292\u2013303","journal-title":"Clin Pharmacol Ther"},{"key":"1825_CR22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/biomet\/73.3.751","volume":"73","author":"RJ Simes","year":"1986","unstructured":"Simes RJ (1986) An improved Bonferroni procedure for multiple hypothesis testing with positively dependent test statistics. Biometrika 73:751\u2013754","journal-title":"Biometrika"},{"key":"1825_CR23","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/01621459.1997.10473682","volume":"92","author":"SK Sarkar","year":"1997","unstructured":"Sarkar SK, Chang CK (1997) The Simes method for multiple hypothesis testing with positively dependent test statistics. J Amer Stat Assoc 92:1601\u20131608","journal-title":"J Amer Stat Assoc"},{"key":"1825_CR24","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106:2865\u20132870","journal-title":"Blood"},{"key":"1825_CR25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0091270007307881","volume":"48","author":"CE Garnett","year":"2008","unstructured":"Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornoe CW, Wang Y, Zhu H, Gobburu JV (2008) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48:13\u201318","journal-title":"J Clin Pharmacol"},{"key":"1825_CR26","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0091270010381498","volume":"51","author":"JA Florian","year":"2011","unstructured":"Florian JA, Tornoe CW, Brundage R, Parekh A, Garnett CE (2011) Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol 51:1152\u20131162","journal-title":"J Clin Pharmacol"},{"key":"1825_CR27","first-page":"401","volume":"18","author":"B Darpo","year":"2011","unstructured":"Darpo B, Fossa AA, Couderc JP, Zhou M, Schreyer A, Ticktin M, Zapesochny A (2011) Improving the precision of QT measurements. Cardiol J 18:401\u2013410","journal-title":"Cardiol J"},{"issue":"Suppl 1","key":"1825_CR28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-200140001-00010","volume":"40","author":"H Stass","year":"2001","unstructured":"Stass H, Sachse R (2001) Effect of probenecid on the kinetics of a single oral 400\u00a0mg dose of moxifloxacin in healthy male volunteers. Clin Pharmacokinet 40(Suppl 1):71\u201376","journal-title":"Clin Pharmacokinet"},{"key":"1825_CR29","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1177\/0091270009356298","volume":"50","author":"JW Mason","year":"2010","unstructured":"Mason JW, Florian JA Jr, Garnett CE, Moon TE, Selness DS, Spaulding RR (2010) Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. J Clin Pharmacol 50:1249\u20131259","journal-title":"J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00280-012-1825-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T10:52:43Z","timestamp":1640602363000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1825-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1825-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,1]]}}}